Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Earnings

Review historical estimates and see whether a company has beaten or missed expectations.

Last Close
Jul 12 04:00PM ET
0.5892
Dollar change
-0.0109
Percentage change
-1.82
%
Index- P/E- EPS (ttm)-0.81 Insider Own34.05% Shs Outstand14.78M Perf Week0.77%
Market Cap8.71M Forward P/E- EPS next Y-0.39 Insider Trans0.17% Shs Float9.75M Perf Month-21.44%
Income-12.36M PEG- EPS next Q-0.09 Inst Own4.20% Short Float0.16% Perf Quarter-39.88%
Sales0.00M P/S- EPS this Y24.22% Inst Trans- Short Ratio0.14 Perf Half Y-45.94%
Book/sh0.21 P/B2.76 EPS next Y20.62% ROA-587.64% Short Interest0.02M Perf Year-
Cash/sh0.24 P/C2.47 EPS next 5Y- ROE-1807.80% 52W Range0.51 - 7.98 Perf YTD-43.89%
Dividend Est.- P/FCF- EPS past 5Y- ROI-391.51% 52W High-92.62% Beta-
Dividend TTM- Quick Ratio5.70 Sales past 5Y0.00% Gross Margin- 52W Low15.53% ATR (14)0.06
Dividend Ex-Date- Current Ratio5.70 EPS Y/Y TTM- Oper. Margin0.00% RSI (14)37.77 Volatility11.12% 7.87%
Employees3 Debt/Eq0.00 Sales Y/Y TTM- Profit Margin- Recom1.00 Target Price13.25
Option/ShortNo / Yes LT Debt/Eq0.00 EPS Q/Q4.18% Payout- Rel Volume0.16 Prev Close0.60
Sales Surprise- EPS Surprise0.00% Sales Q/Q- EarningsMay 29 Avg Volume115.18K Price0.59
SMA20-10.39% SMA50-20.29% SMA200-61.44% Trades Volume18,581 Change-1.82%
Jun-24-24 08:30AM
Jun-10-24 08:30AM
May-29-24 08:45AM
May-21-24 08:45AM
May-20-24 08:00AM
09:53PM Loading…
May-13-24 09:53PM
Apr-02-24 08:00AM
Apr-01-24 02:53PM
Mar-21-24 11:04AM
Mar-08-24 08:19AM
Feb-05-24 08:30AM
Dec-04-23 08:00AM
Nov-29-23 08:00AM
Nov-21-23 10:42AM
10:09AM
08:00AM Loading…
Nov-20-23 08:00AM
Oct-26-23 07:23AM
Sep-18-23 08:30AM
Sep-05-23 08:31AM
Aug-31-23 08:31AM
Aug-29-23 11:39AM
Aug-09-23 09:35AM
Aug-03-23 02:40PM
MIRA Pharmaceuticals, Inc. operates as a clinical development stage biopharmaceutical company. The company engages in developing its product candidate, MIRA1a, as a synthetic cannabinoid analog for treating anxiety & chronic pain by targeting the cannabinoid type 1 and type 2 (CB1 and CB2) receptors. MIRA Pharmaceuticals was founded by Adam Kaplin on September 3, 2020 and is headquartered in Miami, FL.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Aminov ErezChief Executive OfficerMay 21 '24Buy0.948,7008,176382,200May 22 05:42 PM
McNulty Brian Patrick10% OwnerDec 11 '23Sale1.5546,00571,496660,000Dec 27 05:33 PM
McNulty Brian Patrick10% OwnerDec 08 '23Sale1.6119,05330,633683,002Dec 27 05:33 PM
McNulty Brian Patrick10% OwnerDec 07 '23Sale1.8933,33363,156692,529Dec 27 05:33 PM
McNulty Brian Patrick10% OwnerDec 06 '23Sale2.9527,73381,785709,196Dec 27 05:33 PM
McNulty Brian Patrick10% OwnerDec 04 '23Sale3.9861,331244,097723,062Dec 27 05:33 PM
McNulty Brian Patrick10% OwnerNov 30 '23Sale3.774,84218,273753,728Dec 27 05:33 PM
McNulty Brian Patrick10% OwnerNov 29 '23Sale3.987,39929,445756,149Dec 27 05:33 PM
McNulty Brian Patrick10% OwnerNov 28 '23Sale4.00241964759,849Dec 27 05:33 PM
McNulty Brian Patrick10% OwnerNov 27 '23Sale4.006,42525,715759,969Dec 27 05:33 PM
McNulty Brian Patrick10% OwnerNov 21 '23Sale5.005,00025,000763,181Dec 27 05:33 PM
McNulty Brian Patrick10% OwnerNov 20 '23Sale5.0726,733135,523765,681Dec 27 05:33 PM
Cappy George10% OwnerAug 07 '23Buy7.00119,048833,3362,859,318Aug 24 05:38 PM
Cappy George10% OwnerAug 02 '23Buy7.00157,1701,100,1902,740,270Aug 04 01:42 PM